We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Merck's Keytruda Gets Nod for First-Line Lung Cancer in China
Read MoreHide Full Article
Merck & Co., Inc. (MRK - Free Report) announced that its PD-L1 therapy, Keytruda, has gained conditional approval for use in combination with chemotherapies for first-line metastatic nonsquamous non-small cell lung cancer (“NSCLC”) in China. The drug received approval in combination with Eli Lilly’s (LLY - Free Report) Alimta (pemetrexed) and platinum chemotherapy in adult lung cancer patients whose tumors have no EGFR or ALK positive mutations.
A confirmatory study on Chinese patients is required for continued approval in the aforementioned indication. The drug is approved for a similar indication in the United States and Europe. Keytruda is already approved for advanced melanoma in China.
The approval was based on data from a pivotal KEYNOTE-189 study, which demonstrated superiority of Keytruda combination regimen in improving overall survival (“OS”) and progression free survival (“PFS”) over chemotherapy. The Keytruda combination significantly improved overall survival, reducing the risk of death by half (51%) compared to chemotherapy alone. Meanwhile, PFS was also significantly improved. The risk of progression or death was reduced by nearly half (48%) in patients in the Keytruda combination arm versus chemotherapy alone.
So far this year, Merck’s shares have outperformed the industry, rising 9% compared with a 4.9% increase for the industry.
Keytruda has , in a very short time, become the single largest revenue generator for the company with sales of more than $7 billion in 2018. Merck has successfully expanded Keytruda’s label over the years, a significant one being for the first-line lung cancer indication.
Meanwhile, several other pharma companies are looking to get their drugs approved in first-line NSCLC. In June 2018, AstraZeneca’s (AZN - Free Report) Tagrisso received approval for first-line NSCLC in Europe.
The approval in China in first-line lung cancer is likely to further boost the prospects of the drug due to a huge patient population in the country. Per the press release, more than 626,000 patients die in China due to lung cancer every year.
The Keytruda development program is also progressing well and the drug is being studied for more than 30 types of cancer in more than 800 studies, including more than 400 combination studies. Merck is collaborating with several companies including Amgen, Incyte, Glaxo (GSK - Free Report) and Pfizer separately for the evaluation of Keytruda in combination with other regimens. These include several lung cancer studies across multiple settings and stages of the disease, both as a monotherapy as well as a combination therapy.
Would you like to see the updated picks from our best market-beating strategies? From 2017 through 2018, while the S&P 500 gained +15.8%, five of our screens returned +38.0%, +61.3%, +61.6%, +68.1%, and +98.3%.
This outperformance has not just been a recent phenomenon. From 2000 – 2018, while the S&P averaged +4.8% per year, our top strategies averaged up to +56.2% per year.
Image: Bigstock
Merck's Keytruda Gets Nod for First-Line Lung Cancer in China
Merck & Co., Inc. (MRK - Free Report) announced that its PD-L1 therapy, Keytruda, has gained conditional approval for use in combination with chemotherapies for first-line metastatic nonsquamous non-small cell lung cancer (“NSCLC”) in China. The drug received approval in combination with Eli Lilly’s (LLY - Free Report) Alimta (pemetrexed) and platinum chemotherapy in adult lung cancer patients whose tumors have no EGFR or ALK positive mutations.
A confirmatory study on Chinese patients is required for continued approval in the aforementioned indication. The drug is approved for a similar indication in the United States and Europe. Keytruda is already approved for advanced melanoma in China.
The approval was based on data from a pivotal KEYNOTE-189 study, which demonstrated superiority of Keytruda combination regimen in improving overall survival (“OS”) and progression free survival (“PFS”) over chemotherapy. The Keytruda combination significantly improved overall survival, reducing the risk of death by half (51%) compared to chemotherapy alone. Meanwhile, PFS was also significantly improved. The risk of progression or death was reduced by nearly half (48%) in patients in the Keytruda combination arm versus chemotherapy alone.
So far this year, Merck’s shares have outperformed the industry, rising 9% compared with a 4.9% increase for the industry.
Keytruda has , in a very short time, become the single largest revenue generator for the company with sales of more than $7 billion in 2018. Merck has successfully expanded Keytruda’s label over the years, a significant one being for the first-line lung cancer indication.
Meanwhile, several other pharma companies are looking to get their drugs approved in first-line NSCLC. In June 2018, AstraZeneca’s (AZN - Free Report) Tagrisso received approval for first-line NSCLC in Europe.
The approval in China in first-line lung cancer is likely to further boost the prospects of the drug due to a huge patient population in the country. Per the press release, more than 626,000 patients die in China due to lung cancer every year.
The Keytruda development program is also progressing well and the drug is being studied for more than 30 types of cancer in more than 800 studies, including more than 400 combination studies. Merck is collaborating with several companies including Amgen, Incyte, Glaxo (GSK - Free Report) and Pfizer separately for the evaluation of Keytruda in combination with other regimens. These include several lung cancer studies across multiple settings and stages of the disease, both as a monotherapy as well as a combination therapy.
Merck & Co., Inc. Price
Merck & Co., Inc. Price | Merck & Co., Inc. Quote
Zacks Rank
Merck currently has Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Today's Best Stocks from Zacks
Would you like to see the updated picks from our best market-beating strategies? From 2017 through 2018, while the S&P 500 gained +15.8%, five of our screens returned +38.0%, +61.3%, +61.6%, +68.1%, and +98.3%.
This outperformance has not just been a recent phenomenon. From 2000 – 2018, while the S&P averaged +4.8% per year, our top strategies averaged up to +56.2% per year.
See their latest picks free >>